Computational power, AI, genomics: the treatment and diagnosis of prostate cancer is advancing rapidly. This episode finds out how. A leap forward in the diagnosis and treatment would be very welcome: prostate cancer is the second most frequent malignancy in men. In 2020 alone, around one and a half million new cases and almost half a million deaths were registered worldwide. To explore new diagnostics and treatment are: Jan Tkac, founder and chief scientific officer at Glycanostics, in Slovakia. The company has developed an innovative diagnostic test for cancer, based on novel biomarkers. Jan is also keen to explore how different sports relate to the levels of endorphin release. Harald Mischak, chief scientific officer of Mosaiques Diagnostics & Therapeutics, Germany. Harald is focused on understanding the underlying molecular structures of certain types of cancers. Joaquin Mateo, group leader of the Prostate Cancer Translational Research Group at Vall d’Hebron Institute of Oncology, in Barcelona. He is especially interested in the development of novel forms of precision medicine. For more info on the projects featured, visit: https://europa.eu/!dgTGkb

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related